Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 14,241 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Diseases of the Digestive System Clear all
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Active, not recruiting No phase listed Observational

Methodist Acute Pancreatitis Protocol

NCT04214756
View directory record Official record
Conditions
Acute Pancreatitis (AP)
Interventions
Acute Pancreatitis
Procedure
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
500 participants
Timeline
2014 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT02065622
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Adalimumab, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
42
States / cities
Dothan, Alabama • La Jolla, California • Wheat Ridge, Colorado + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 2:27 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

NCT03596645
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Golimumab, Infliximab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Lone Tree, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 2:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

NCT06096688
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 2 Interventional

Recurrent Abdominal Pain in Children

NCT00526903
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome
Interventions
Elimination Diet
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 18 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

NCT03535727
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
Interventions
Nab-paclitaxel, Gemcitabine, Capecitabine, Cisplatin, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 76 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Not applicable Interventional

RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease

NCT03365531
View directory record Official record
Conditions
NAFLD, Obesity, Diabetes Mellitus, Type 2
Interventions
Alternate Daily Fasting (ADF), Caloric Restriction (CR)
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Early Intervention in Cystic Fibrosis Exacerbation

NCT01104402
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Home lung function and symptom monitoring
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

NCT02401737
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NVR 3-778, Placebo for NVR 3-778, Pegasys
Drug
Lead sponsor
Novira Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Costa Mesa, California • Pasadena, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)

NCT00992589
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
1 Month to 11 Months
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Columbiana, Alabama • Dothan, Alabama + 40 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Not applicable Interventional Results available

Edwards CLASP TR EFS

NCT03745313
View directory record Official record
Conditions
Tricuspid Regurgitation
Interventions
Edwards PASCAL Transcatheter Valve Repair System
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 2:27 PM EDT
Completed No phase listed Observational

Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails

NCT04036760
View directory record Official record
Conditions
Hepatitis C
Interventions
Research transitional care coordination
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 22, 2026, 2:27 PM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jul 22, 2026, 2:27 PM EDT
Not listed Phase 2Phase 3 Interventional

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

NCT00547469
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP733
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
62
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2008 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 22, 2026, 2:27 PM EDT
Terminated Phase 2 Interventional

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00103103
View directory record Official record
Conditions
Gastric Cancer
Interventions
bortezomib, fluorouracil, leucovorin calcium
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Jul 22, 2026, 2:27 PM EDT
Withdrawn No phase listed Observational

Liver, Pancreas and Thyroid Function in Burn Patients

NCT03598283
View directory record Official record
Conditions
Burns, Liver Fibroses, Pancreas Disease, Thyroid Diseases
Interventions
Ultrasound/transient elastography
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
6 Months and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Jul 22, 2026, 2:27 PM EDT